- Home
- BIOA vs MCRB Comparison
BIOA vs MCRB Comparison
Compare BIOA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- MCRB
- Stock Information
- Founded
- BIOA 2015
- MCRB 2010
- Country
- BIOA United States
- MCRB United States
- Employees
- BIOA N/A
- MCRB N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- MCRB Health Care
- Exchange
- BIOA Nasdaq
- MCRB Nasdaq
- Market Cap
- BIOA 175.7M
- MCRB 144.6M
- IPO Year
- BIOA 2024
- MCRB 2015
- Fundamental
- Price
- BIOA $5.45
- MCRB $18.69
- Analyst Decision
- BIOA Hold
- MCRB Hold
- Analyst Count
- BIOA 4
- MCRB 4
- Target Price
- BIOA $5.67
- MCRB $14.33
- AVG Volume (30 Days)
- BIOA 189.4K
- MCRB 262.7K
- Earning Date
- BIOA 11-06-2025
- MCRB 11-12-2025
- Dividend Yield
- BIOA N/A
- MCRB N/A
- EPS Growth
- BIOA N/A
- MCRB N/A
- EPS
- BIOA N/A
- MCRB 10.22
- Revenue
- BIOA $3,863,000.00
- MCRB N/A
- Revenue This Year
- BIOA N/A
- MCRB N/A
- Revenue Next Year
- BIOA N/A
- MCRB N/A
- P/E Ratio
- BIOA N/A
- MCRB $1.84
- Revenue Growth
- BIOA N/A
- MCRB N/A
- 52 Week Low
- BIOA $2.88
- MCRB $6.53
- 52 Week High
- BIOA $26.62
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- BIOA 63.40
- MCRB 54.20
- Support Level
- BIOA $4.88
- MCRB $18.40
- Resistance Level
- BIOA $5.34
- MCRB $19.90
- Average True Range (ATR)
- BIOA 0.26
- MCRB 1.73
- MACD
- BIOA 0.04
- MCRB 0.00
- Stochastic Oscillator
- BIOA 95.06
- MCRB 77.74
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.